FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 756 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Shaping Cancer Care in Asia: ESMO Brings Research and Patient Voices... November 28, 2025 Visits to Online Breast Cancer Communities Could Help Policy Makers and... February 11, 2021 Tips On Staying Cool During a Heat Wave June 30, 2021 FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL July 29, 2021 Load more HOT NEWS 2021/22 in review: Charity looks to the future with ambitious new... ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large... The Recently Leaked Secret to Marijuana News Discovered Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,...
